These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24148668)

  • 1. Impact of differential surface molecular environment on the interparticulate bonding strength of celecoxib crystal habits.
    Modi SR; Khomane KS; Bansal AK
    Int J Pharm; 2014 Jan; 460(1-2):189-95. PubMed ID: 24148668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion.
    Puri V; Dantuluri AK; Bansal AK
    J Pharm Sci; 2011 Jun; 100(6):2460-8. PubMed ID: 21246560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advantages of celecoxib nanosuspension formulation and transformation into tablets.
    Dolenc A; Kristl J; Baumgartner S; Planinsek O
    Int J Pharm; 2009 Jul; 376(1-2):204-12. PubMed ID: 19426794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug: influence of pore size on release rate.
    Zhu W; Wan L; Zhang C; Gao Y; Zheng X; Jiang T; Wang S
    Mater Sci Eng C Mater Biol Appl; 2014 Jan; 34():78-85. PubMed ID: 24268236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of crystal morphology and mill type on milling induced crystal disorder.
    Chikhalia V; Forbes RT; Storey RA; Ticehurst M
    Eur J Pharm Sci; 2006 Jan; 27(1):19-26. PubMed ID: 16246535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of the crystal habit of celecoxib for improved processability.
    Banga S; Chawla G; Varandani D; Mehta BR; Bansal AK
    J Pharm Pharmacol; 2007 Jan; 59(1):29-39. PubMed ID: 17227618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
    Dhumal RS; Shimpi SL; Paradkar AR
    Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of surface energy on powder compactibility.
    Fichtner F; Mahlin D; Welch K; Gaisford S; Alderborn G
    Pharm Res; 2008 Dec; 25(12):2750-9. PubMed ID: 18548337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Holistic Multi Evidence Approach to Study the Fragmentation Behaviour of Crystalline Mannitol.
    Koner JS; Rajabi-Siahboomi A; Bowen J; Perrie Y; Kirby D; Mohammed AR
    Sci Rep; 2015 Nov; 5():16352. PubMed ID: 26553127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A material-sparing method for simultaneous determination of true density and powder compaction properties--aspartame as an example.
    Sun CC
    Int J Pharm; 2006 Dec; 326(1-2):94-9. PubMed ID: 16926076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and evaluation of celecoxib porous particles using melt sonocrystallization.
    Paradkar A; Maheshwari M; Kamble R; Grimsey I; York P
    Pharm Res; 2006 Jun; 23(6):1395-400. PubMed ID: 16741659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Devitrification of amorphous celecoxib.
    Gupta P; Bansal AK
    AAPS PharmSciTech; 2005 Sep; 6(2):E223-30. PubMed ID: 16353981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential.
    Remenar JF; Peterson ML; Stephens PW; Zhang Z; Zimenkov Y; Hickey MB
    Mol Pharm; 2007; 4(3):386-400. PubMed ID: 17497886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different or the same? exploring the physicochemical properties and molecular mobility of celecoxib amorphous forms.
    Wang M; Aalling-Frederiksen O; Madsen AØ; Jensen KMØ; Jørgensen MRV; Gong J; Rades T; Martins ICB
    Int J Pharm; 2024 Aug; 661():124470. PubMed ID: 39004294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spherical crystals of celecoxib to improve solubility, dissolution rate and micromeritic properties.
    Gupta VR; Mutalik S; Patel MM; Jani GK
    Acta Pharm; 2007 Jun; 57(2):173-84. PubMed ID: 17507314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and physicochemical and preclinical evaluations of recrystallized celecoxib.
    Mutalik S; Usha N; Ranjith AK; Umesh S; Musmade P; Anup N
    PDA J Pharm Sci Technol; 2007; 61(5):362-74. PubMed ID: 18047175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved tableting properties of p-hydroxybenzoic acid by water of crystallization: a molecular insight.
    Sun C; Grant DJ
    Pharm Res; 2004 Feb; 21(2):382-6. PubMed ID: 15032322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of spray-drying to enhance celecoxib solubility.
    Fouad EA; El-Badry M; Mahrous GM; Alanazi FK; Neau SH; Alsarra IA
    Drug Dev Ind Pharm; 2011 Dec; 37(12):1463-72. PubMed ID: 21707230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of dry granulation on compactibility and capping tendency of macrolide antibiotic formulation.
    Bozic DZ; Dreu R; Vrecer F
    Int J Pharm; 2008 Jun; 357(1-2):44-54. PubMed ID: 18308490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug.
    Puri V; Dantuluri AK; Kumar M; Karar N; Bansal AK
    Eur J Pharm Sci; 2010 May; 40(2):84-93. PubMed ID: 20230893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.